Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) – Retinitis Pigmentosa GTPase Regulator (RPGR)

In this page

Clinical Trial

NCT03252847 Completed
Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) – Retinitis Pigmentosa GTPase Regulator (RPGR)

An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2-.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)

Phase 1/2
Interventional

Disease

Disease type

Hereditary retinal disease

Retinitis Pigmentosa

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

14/07/2017

Closing date

18/11/2021

Inclusion criteria :

More

Exclusion criteria :

More

Funding

private

Members involved

Others investigators

Pr Luca Rossetti

Representative

Italy

See more

ERN EYE member investigating site

HCP : Principal investigators